Review of gout clinic in a tertiary hospital setting

Although updated consensus guidelines, and effective therapies, are available for management of gout, suboptimal management remains an issue. Barriers were identified and addressed as part of a dedicated, structured gout clinic. More frequent appointments resulted in a faster rate of serum urate reduction, and the clinic provided the opportunity for the education of both patients and general practitioners in the management of gout.

[1]  N. Zethraeus,et al.  Cost‐effectiveness of an adherence‐enhancing intervention for gout based on real‐world data , 2018, International journal of rheumatic diseases.

[2]  L. Duley,et al.  Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial , 2018, The Lancet.

[3]  Hyon K. Choi,et al.  Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies , 2018, Rheumatology.

[4]  P. Richette,et al.  FRI0235 Effect of serum uric acid (SUA) on gout flares (GF) and tophi resolution in gout patients. pooled post hoc analysis of clear 1 & clear 2 trials , 2018, FRIDAY, 15 JUNE 2018.

[5]  O. Zhelyabina,et al.  FRI0226 Assessment of therapy adherence and treatment results in gout patients who attended schools for patients and in those who did not , 2018, FRIDAY, 15 JUNE 2018.

[6]  T. A. Popova,et al.  AB1019 Patients compliance to chronic gout therapy when administered by different medical professionals , 2018, Osteoarthritis.

[7]  O. Slot.  Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment , 2018, Scandinavian journal of rheumatology.

[8]  F. Lioté,et al.  Gout: state of the art after a decade of developments , 2018, Rheumatology.

[9]  J. Fitzgerald,et al.  Treatment approaches and adherence to urate-lowering therapy for patients with gout , 2017, Patient preference and adherence.

[10]  T. Gill,et al.  Prevalence and associations of gout and hyperuricaemia: results from an Australian population‐based study , 2016, Internal medicine journal.

[11]  M. Doherty,et al.  Global epidemiology of gout: prevalence, incidence and risk factors , 2015, Nature Reviews Rheumatology.

[12]  W. Taylor,et al.  An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population , 2015, The Journal of Rheumatology.

[13]  L. Stamp,et al.  Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout , 2014, Drugs & Aging.

[14]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[15]  T. Vos,et al.  The global burden of gout: estimates from the Global Burden of Disease 2010 study , 2014, Annals of the rheumatic diseases.

[16]  C. Bombardier,et al.  Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative , 2013, Annals of the rheumatic diseases.

[17]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[18]  F. Perez-Ruiz,et al.  Treat to target in gout , 2018, Rheumatology.

[19]  L. Kozina,et al.  [Gout and hyperuricemia today: prevalence, risk factors, features in the elderly]. , 2012, Advances in gerontology = Uspekhi gerontologii.